Skip to content
Dr Ioannis SpiliotisThe Hertfordshire Endocrine & Metabolic Clinic

About

Dr Ioannis Spiliotis

Consultant Endocrinologist & Diabetologist

MBBS DPhil MRCP · GMC 7044495

Dr Ioannis Spiliotis is a Consultant in Diabetes, Endocrinology and General Medicine at Milton Keynes University Hospital. He qualified in medicine at University College London in 2009, after a first-class degree in molecular biology at King's College London. He completed both his specialty training in diabetes and endocrinology and his doctorate in Oxford, on the academic clinical pathway: first as an Academic Clinical Fellow, then, after an NIHR-funded DPhil in Medical Sciences at the University of Oxford's Centre for Diabetes, Endocrinology and Metabolism (OCDEM), as a Clinical Lecturer. He is an honorary researcher at the University of Oxford.

I aim to explain what I have found, what I think it means, and what the options are.

Dr Ioannis Spiliotis
Dr Ioannis Spiliotis

Clinical practice

What Dr Spiliotis sees

Dr Spiliotis sees a wide range of endocrine and metabolic conditions: thyroid disease, diabetes and diabetes technology (including less common and harder-to-classify forms such as monogenic diabetes, MODY), weight and metabolic health (including weight management in type 1 diabetes), PCOS / PMOS and women's hormone health, pituitary and adrenal disorders, parathyroid and calcium disorders, and men's hormone health.

Within the NHS he leads inpatient diabetes care and the young-adult transition service, co-leads the multidisciplinary diabetic foot clinic, works within the insulin pump team on hybrid closed-loop care, and co-authors hospital-wide clinical guidelines in diabetes and endocrinology.

Qualifications

Training & credentials

  • MBBS, with distinctionsUniversity College London, 2009
  • BSc (Hons), First Class, Molecular BiologyKing's College London, 2004
  • MRCP (UK)Royal College of Physicians, 2012
  • PGDip in Health ResearchUniversity of Oxford, 2014
  • DPhil in Medical SciencesUniversity of Oxford (OCDEM), 2019
  • Specialty Certificate in Diabetes & EndocrinologyRoyal College of Physicians, 2021
  • Certificate of Completion of Training, endocrinology and diabetes mellitus and general internal medicineGeneral Medical Council, 2023

Full GMC registration with a licence to practise, and on the GMC specialist register.

Research

Research & clinical trials

Dr Spiliotis's research focuses on the hormonal regulation of blood glucose, and in particular on glucagon and the prevention of hypoglycaemia in diabetes. He is Chief Investigator of the LEGEND-D trial, published in eBioMedicine in 2026, and was previously Chief Investigator of the LEGEND-A pilot, the Glucagon in MODY study and the DEPTH exercise study.

He is local Principal Investigator for the ACTIVATE trial (digital health in type 2 diabetes), and site Principal Investigator for VAPOR 1 (a pancreatic cancer biomarker study) and for a clinical evaluation of a continuous glucose monitoring system.

Dr Ioannis Spiliotis carrying out laboratory research

In the laboratory

Research-led care

His laboratory work, in the Rorsman laboratory at OCDEM, studied how the hormones that control blood glucose regulate one another, and what happens when that control fails in diabetes and hypoglycaemia.

The same way of thinking informs how he chooses investigations and reads results.

Selected publications

Peer-reviewed work

  1. Gao R, Spiliotis I, Dou H, et al. Partial restoration of counterregulatory circulating glucagon by dapagliflozin and low-dose glibenclamide in men with type 1 diabetes: in vitro studies and randomised clinical crossover trial. eBioMedicine. 2026.
  2. Walsh CM, ..., Spiliotis I, et al. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control study. BMJ Open. 2025.
  3. Hamblin R, ..., Spiliotis I, et al. Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance. Lancet Diabetes & Endocrinology. 2022.
  4. Spiliotis II, Chalk R, Gough S, Rorsman P. Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: results of the LEGEND-A pilot study. Diabetes, Obesity and Metabolism. 2022.
  5. Vergari E, ..., Spiliotis I, et al. Somatostatin secretion by Na+-dependent Ca2+-induced Ca2+ release in pancreatic delta-cells. Nature Metabolism. 2020.
  6. Vergari E, ..., Spiliotis II, et al. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nature Communications. 2019.
  7. Dwivedi OP, ..., Spiliotis I, et al. Loss of ZnT8 function protects against diabetes by enhanced insulin secretion. Nature Genetics. 2019.

A note on regulation and transparency. Private work is carried out under professional indemnity and in line with the GMC's Good Medical Practice. The private practice is separate from Dr Spiliotis's NHS role and does not use NHS resources. Dr Spiliotis holds no financial interest in the hospitals, laboratories or pharmacies the practice uses; if that changes, it will be stated here and explained to you before any referral. The practice takes no margin on medicines; the pharmacy charges its own price for the medicine. Prescription fees are set out on the Fees page.